Edition:
United States

Kalvista Pharmaceuticals Inc (KALV.OQ)

KALV.OQ on NASDAQ Stock Exchange Global Market

11.08USD
2:29pm EST
Change (% chg)

$0.24 (+2.21%)
Prev Close
$10.84
Open
$10.93
Day's High
$11.08
Day's Low
$10.85
Volume
1,101
Avg. Vol
30,475
52-wk High
$15.75
52-wk Low
$5.48

Chart for

About

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein... (more)

Overall

Beta: --
Market Cap(Mil.): $116.90
Shares Outstanding(Mil.): 10.78
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.23 16.73
EPS (TTM): -- -- --
ROI: -- 14.02 35.60
ROE: -- 15.49 17.23

BRIEF-Kalvista Pharmaceuticals Commences Two Clinical Trials

* KALVISTA PHARMACEUTICALS INC - TOP-LINE RESULTS ARE EXPECTED IN SECOND HALF OF 2019 FOR KVD001

Jan 05 2018

BRIEF-Kalvista Pharmaceuticals Reports Q2 Loss Per Share $0.50

* KALVISTA PHARMACEUTICALS REPORTS FISCAL SECOND QUARTER RESULTS

Dec 14 2017

BRIEF-Ra Capital Management says it purchased 850,000 shares of Kalvista Pharmaceuticals' common stock for about $7.2 mln

* Ra Capital Management says ‍​on Oct 12, it purchased 850,000 shares of Kalvista Pharmaceuticals' common stock for about $7.2 million - SEC Filing

Nov 13 2017

BRIEF-Longwood Fund II reports 8.7 pct stake in Kalvista Pharmaceuticals ‍​

* Longwood Fund II Lp reports 8.7 pct stake in Kalvista Pharmaceuticals Inc as of Oct 12 - sec filing‍​ Source text - http://bit.ly/2xTHJJO Further company coverage:

Oct 20 2017

BRIEF-Kalvista Pharmaceuticals announces collaboration with Merck

* Kalvista Pharmaceuticals announces collaboration with Merck

Oct 10 2017

BRIEF-KalVista Pharmaceuticals reports Q1 loss per share of $0.51

* KalVista pharmaceuticals reports fiscal first quarter results

Sep 14 2017

Earnings vs. Estimates